Pyrotinib alone or in combination with docetaxel in refractory HER2‐positive gastric cancer: A dose‐escalation phase I study

AIM: Pyrotinib (an irreversible pan‐ErbB small‐molecular tyrosine kinase inhibitor) was approved in human epidermal growth factor receptor 2 (HER2)‐positive breast cancer and showed great antitumor activity in preclinical studies of gastric cancer (GC). This study was first designed to prospectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Dan, Kou, Furong, Gong, Jifang, Wang, Zhiqiang, Zhang, Xiaotian, Li, Jian, Li, Yan, Li, Jie, Zhou, Jun, Lu, Ming, Wang, Xicheng, Lu, Zhihao, Cao, Yanshuo, Zou, Jianjun, Zhu, Xiaoyu, Xu, Ruihua, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225203/
https://www.ncbi.nlm.nih.gov/pubmed/37081722
http://dx.doi.org/10.1002/cam4.5830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225203/
https://www.ncbi.nlm.nih.gov/pubmed/37081722
http://dx.doi.org/10.1002/cam4.5830

Ejemplares similares